Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
2008 1
2009 1
2010 1
2011 1
2012 3
2013 2
2014 6
2015 5
2016 7
2017 4
2018 7
2019 9
2020 7
2021 6
2022 3
2023 4
2024 2
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

59 results

Results by year

Filters applied: . Clear all
Page 1
Tofacitinib versus methotrexate in rheumatoid arthritis.
Lee EB, Fleischmann R, Hall S, Wilkinson B, Bradley JD, Gruben D, Koncz T, Krishnaswami S, Wallenstein GV, Zang C, Zwillich SH, van Vollenhoven RF; ORAL Start Investigators. Lee EB, et al. N Engl J Med. 2014 Jun 19;370(25):2377-86. doi: 10.1056/NEJMoa1310476. N Engl J Med. 2014. PMID: 24941177 Free article. Clinical Trial.
Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty-Four-Month, Phase III Study.
van der Heijde D, Strand V, Tanaka Y, Keystone E, Kremer J, Zerbini CAF, Cardiel MH, Cohen S, Nash P, Song YW, Tegzová D, Gruben D, Wallenstein G, Connell CA, Fleischmann R; ORAL Scan Investigators. van der Heijde D, et al. Arthritis Rheumatol. 2019 Jun;71(6):878-891. doi: 10.1002/art.40803. Epub 2019 Apr 24. Arthritis Rheumatol. 2019. PMID: 30666826 Free PMC article. Clinical Trial.
Olokizumab versus Placebo or Adalimumab in Rheumatoid Arthritis.
Smolen JS, Feist E, Fatenejad S, Grishin SA, Korneva EV, Nasonov EL, Samsonov MY, Fleischmann RM; CREDO2 Group. Smolen JS, et al. N Engl J Med. 2022 Aug 25;387(8):715-726. doi: 10.1056/NEJMoa2201302. N Engl J Med. 2022. PMID: 36001712 Clinical Trial.
Fracture risk assessment in Latin America: is Frax an adaptable instrument for the region?
Morales-Torres J, Clark P, Delezé-Hinojosa M, Cons-Molina F, Messina OD, Hernández J, Jaller-Raad JJ, Quevedo-Solidoro H, Radominski SC. Morales-Torres J, et al. Among authors: radominski sc. Clin Rheumatol. 2010 Oct;29(10):1085-91. doi: 10.1007/s10067-010-1489-0. Epub 2010 Jul 15. Clin Rheumatol. 2010. PMID: 20632196 Review.
Safety of upadacitinib in Latin American patients with rheumatoid arthritis: an integrated safety analysis of the SELECT phase 3 clinical program.
Kakehasi AM, Radominski SC, Baravalle MD, Palazuelos FCI, Garcia-Garcia C, Arruda MS, Curi M, Liu J, Qiao M, Velez-Sanchez P, Vargas JI. Kakehasi AM, et al. Among authors: radominski sc. Clin Rheumatol. 2023 May;42(5):1249-1258. doi: 10.1007/s10067-023-06513-y. Epub 2023 Jan 30. Clin Rheumatol. 2023. PMID: 36715850 Free PMC article. Clinical Trial.
Predictors of serious infections in rheumatoid arthritis-a prospective Brazilian cohort.
de Almeida ALB, Guimarães MFBR, da Costa Pinto MR, Pereira LR, Reis APMG, Bonfiglioli KR, Louzada-Junior P, Giorgi RDN, de Castro GRW, Radominski SC, Brenol CV, Pugliesi A, da Mota LMH, da Rocha Castelar-Pinheiro G. de Almeida ALB, et al. Among authors: radominski sc. Adv Rheumatol. 2024 Mar 29;64(1):23. doi: 10.1186/s42358-024-00363-1. Adv Rheumatol. 2024. PMID: 38553751
Treatment of knee osteoarthritis with a new formulation of a fixed-dose combination of glucosamine sulfate and bovine chondroitin: a multicenter, randomized, single-blind, non-inferiority clinical trial.
Lomonte ABV, Gimenez E, da Silva AC, Radominski SC, Scheinberg MA, Ximenes AC, de Freitas Zerbini CA. Lomonte ABV, et al. Among authors: radominski sc. Adv Rheumatol. 2021 Jan 19;61(1):7. doi: 10.1186/s42358-021-00165-9. Adv Rheumatol. 2021. PMID: 33468249 Clinical Trial.
Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
Kivitz A, Olech E, Borofsky M, Zazueta BM, Navarro-Sarabia F, Radominski SC, Merrill JT, Rowell L, Nasmyth-Miller C, Bao M, Wright S, Pope JE. Kivitz A, et al. Among authors: radominski sc. Arthritis Care Res (Hoboken). 2014 Nov;66(11):1653-61. doi: 10.1002/acr.22384. Arthritis Care Res (Hoboken). 2014. PMID: 24942540 Free PMC article. Clinical Trial.
Extra-articular manifestations of rheumatoid arthritis remain a major challenge: data from a large, multi-centric cohort.
Bonfiglioli KR, de Medeiros Ribeiro AC, Carnieletto AP, Pereira I, Domiciano DS, da Silva HC, Pugliesi A, Pereira LR, Guimarães MFR, Giorgi RDN, Reis APMG, Brenol CV, Louzada-Júnior P, da Cunha Sauma MFL, Radominski SC, da Mota LMH, da Rocha Castelar-Pinheiro G. Bonfiglioli KR, et al. Among authors: radominski sc. Adv Rheumatol. 2023 Jul 26;63(1):34. doi: 10.1186/s42358-023-00318-y. Adv Rheumatol. 2023. PMID: 37496102
Do it fast! Early access to specialized care improved long-term outcomes in rheumatoid arthritis: data from the REAL multicenter observational study.
Albuquerque CP, Reis APMG, Vargas Santos AB, Bértolo MB, Júnior PL, Neubarth Giorgi RD, Radominski SC, Guimarães MFBR, Bonfiglioli KR, L Cunha Sauma MF, Pereira IA, Brenol CV, Henrique Mota LM, Santos-Neto L, Castelar Pinheiro GR. Albuquerque CP, et al. Among authors: radominski sc. Adv Rheumatol. 2023 Apr 24;63(1):17. doi: 10.1186/s42358-023-00301-7. Adv Rheumatol. 2023. PMID: 37095556
59 results